Abstract
Introduction: MCI is considered as a prodromal stage between normal cognitive aging and dementia given its potential to develop into various forms of dementia, most notably Alzheimer’s disease (AD). This translates to a need for effective pharmacological and non-pharmacological treatments to prevent the progression of MCI and subsequently slowing AD onset. This review aims to discuss the effectiveness of pharmacological and non-pharmacological interventions in slowing MCI progression. Methods: A literature search was conducted using the PubMed database for randomized controlled trials (RCTs) examining the effectiveness of interventions with individuals with MCI. Keywords included “mild cognitive impairment”, “drug”, “treatment”, and “randomized controlled trials”. Articles were evaluated on criteria relevant to the review’s purpose. Results: Studies on different pharmacological and non-pharmacological interventions demonstrated promising results in slowing the progression of MCI into dementia. Acetylcholinesterase inhibitors (AChEIs) display favourable results on multiple cognitive assessments when compared to placebo. Non-pharmacological interventions, such as diet supplementation or exercise, also have the potential in improving performance in a multitude of cognitive domains. Discussion: In multiple RCTs, AChEIs displayed effectiveness in alleviating cognitive impairment associated with MCI, but only temporarily with some adverse effects. Given the difficulty in determining a clear use of AChEIs on slowing the progression of MCI, additional research is needed. Non-pharmacological interventions have also displayed effectiveness without risk of adverse drug effects. Literature regarding multimodal approaches combining both pharmacological and non-pharmacological interventions is a novel area of research, and these studies have suggested positive additive effects. Conclusion: Pharmacological and non-pharmacological interventions for slowing the progression of MCI display promising results. More studies are needed to determine which treatment plans, whether pharmacological, non-pharmacological, or a combination of the two, will prove to be the most effective for individuals with MCI.
Highlights
Mild cognitive impairment (MCI) is considered as a prodromal stage between normal cognitive aging and dementia given its potential to develop into various forms of dementia, most notably Alzheimer’s disease (AD)
This translates to the need for effective pharmacological and non-pharmacological treatments to prevent the progression of MCI and subsequently slow the onset of AD
The primary measures displayed no significant difference between donepezil and placebo groups, secondary measures showed promising efficacy of donepezil
Summary
MCI is considered as a prodromal stage between normal cognitive aging and dementia given its potential to develop into various forms of dementia, most notably Alzheimer’s disease (AD). This translates to a need for effective pharmacological and non-pharmacological treatments to prevent the progression of MCI and subsequently slowing AD onset. It is estimated that 10-54% of MCI diagnoses will develop into dementia per year, and 10-15% will develop into AD [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
